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Abstract
Plasmepsins (PMs) are essential proteases of the plasmodia parasites and are therefore promising targets
for developing drugs against malaria. We have discovered six inhibitors of PM II by high-throughput
fragment-based docking of a diversity set of approximately 40,000 molecules, and consensus scoring
with force field energy functions. Using the common scaffold of the three most active inhibitors
(IC(50)=2-5 microM), another seven inhibitors were identified by substructure search. Furthermore,
these 13 inhibitors belong to at least three different classes of compounds. The in silico approach was
very effective since a total of 13 active compounds were discovered by testing only 59 molecules in an
enzymatic assay. This hit rate is about one to two orders of magnitude higher than those reported for
medium- and high-throughput screening techniques in vitro. Interestingly, one of the inhibitors
identified by docking was halofantrine, an antimalarial drug of unknown mechanism. Explicit water
molecular dynamics simulations were used to discriminate between two putative binding modes of
halofantrine in PM II.
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Abstract
Friedman et al. 2
Plasmepsins (PMs) are essential proteases of the plasmodia parasites and are
therefore promising targets for developing drugs against malaria. We have discov-
ered six inhibitors of PM II by high-throughput fragment-based docking of a diversity
set of about 40000 molecules, and consensus scoring with force field energy func-
tions. Using the common scaffold of the three most active inhibitors (which have
IC50 values of 2 to 5 µM), another seven inhibitors were identified by substructure
search. Furthermore, the 13 inhibitors belong to at least three different classes
of compounds. The in silico approach is very effective since a total of 13 active
compounds were discovered by testing only 59 molecules in an enzymatic assay.
This hit rate is about one to two orders of magnitude higher than those reported
for medium- and high-throughput screening techniques in vitro. Interestingly, one of
the inhibitors identified by docking is halofantrine, an antimalarial drug of unknown
mechanism. Explicit water molecular dynamics simulations are used to discriminate
between two putative binding modes of halofantrine in PM II.
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Introduction
There is an urgent need to develop potent antimalarial medications due to emerging
drug resistance [1]. Many efforts are aimed at inhibition of plasmodial proteases,
which are involved in metabolism and host cell invasion [2]. Plasmepsins (PMs) are
pepstatin-like aspartic proteases unique to plasmodia. Ten PMs have been identi-
fied in the genome of P. falciparum, the plasmodium species that causes the most
fatal form of malaria in human, and four of these 10 are located in the food vacuole,
an acidic lysosome-like organelle in which haemoglobin degradation takes place.
Inhibitors of PMs are fatal to the parasites [3], which indicates that PMs are relevant
drug targets (see Ref [3] for a comprehensive list of known PM II inhibitors). Further-
more, several small-molecule inhibitors of retroviral and human aspartic proteases,
namely HIV-protease [4] and renin [5], are effective and safe medicines, which pro-
vides additional support to the relevance of PMs as drug targets.
Several computational studies of PMs have been reported in the past three
years. The computational approaches used for PM inhibitor development range
from modeling of compounds in the binding site [6, 7] to homology modeling of PM,
docking, and molecular dynamics (MD) simulations [8, 9]. On the other hand, no
high-throughput docking into the active site of PMs followed by experimental valida-
tion has been published as of today.
Here we report on the discovery of novel PM inhibitors by high-throughput fragment-
based docking of a set of 40000 molecules obtained by 2D structural clustering of
an initial library of 4.6 million compounds. A similar in silico fragment-based ap-
proach had been used previously to identify novel inhibitors of the aspartic protease
β-secretase [10, 11], two kinases [12, 13], and a flaviviral serine protease [14]. The
major difference between our previous in silico screening campaigns and the one
reported here is the final scoring of the poses. In fact, poses were sorted in the past
by a single energy function, while consensus scoring, precisely the median rank of
four force field-based energy functions, is used here. The four energy functions are:
The binding free energy approximated by the linear interaction energy with contin-
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uum electrostatics (LIECE) method [15], the CHARMm [16] electrostatic interaction
energy, the CHARMm van der Waals efficiency, and the TAFF [17] interaction en-
ergy. Only 59 molecules were tested in an enzymatic assay, and 13 of them show
inhibitory activity (IC50 < 100 µM; IC50 = concentration of inhibitor at which 50% of
the maximum initial rate is observed). Furthermore, four of these 13 compounds
have an IC50 value between 2 and 5 µM. Remarkably, one of these four inhibitors
is the antimalarial drug halofantrine, whose mechanism of action is still not clear
although halofantrine was discovered four decades ago and is on the market since
1988. The binding mode of halofantrine in PM II is studied by multiple explicit water
MD simulations.
Results and Discussion
Validation of the LIECE model for PM II
The three-parameter LIECE model for PM II was fitted to 20 peptidic inhibitors
(see Methods). The values of the LIECE parameters (see Equation 1) are α =
0.20(±0.04), β = 0.05(±0.01) and ∆Gtr,rot = 6.0(±2.5) kcal/mol, where the standard
deviation in parentheses is calculated by using the 20 LIECE models obtained by
the leave-one-out procedure. The free energy of binding calculated by LIECE has
a root mean square error of 1.0 kcal/mol for the 20 known inhibitors used for fitting,
with a maximal unsigned error of 1.7 kcal/mol (Table 2). A cross-validated corre-
lation coefficient q2 of 0.60 is obtained by the leave-one-out (LOO) procedure. To
provide further evidence against chance correlation in the LIECE model a scram-
bling test of the data points was performed. The experimental values of binding
affinity were randomly permuted 10000 times resulting in 10000 random data sets.
In this way, 10000 random models were generated by fitting to the random data sets.
A scatter plot of the correlation coefficient values versus the LOO cross-validated q2
values is shown in Figure 1 for the random models and the true LIECE model. The
statistically most significant model (highest LOO cross-validated q2) is the LIECE
model fitted to the original (i.e., unpermuted) data points (red triangle in Figure 1),
Friedman and Caflisch 5
which provides strong evidence that the LIECE model of PM II does not suffer of
chance correlation.
Validation of consensus scoring
To check if consensus scoring is able to identify known inhibitors, the median rank
was calculated for the 20 peptidic inhibitors used for the LIECE model fitting. Ten
of the 20 inhibitors have the top 10 median ranks among the 40000 compounds.
Of the remaining 10 inhibitors, eight have a median rank below 200, while inhibitors
4 and 5 have median ranks of 12902 and 25457, respectively. The 18 inhibitors
in the first 200 ranks score well in three of the four energy functions and poorly in
the van der Waals efficiency, mainly because of their size. The molecular weight
of the 20 peptidic inhibitors is 627 ± 78 Da, compared with 333 ± 99 Da for the
40000 docked compounds. Furthermore, inhibitors 4 and 5 have very unfavorable
CHARMM electrostatic interaction energy as they have a negative charge (carboxyl
group) and the net charge of PM II is -17 electronic units. The very good ranks of the
known inhibitors indicate that consensus scoring is appropriate for high throughput
docking.
The 40000 docked compounds (which include 6 actives) were ranked together
with the 20 peptidic inhibitors and the 7 inhibitors identified by substructure search
to compare the predictive power of individual energy functions and consensus scor-
ing. The Receiver Operating Characteristic (ROC) plot (Figure 2) shows that con-
sensus scoring yields the highest enrichment factor if one examines up to the first
1000 compounds while the TAFF energy function is the best if one takes into ac-
count larger sets of compounds. One should note that only the top-ranking 500
compounds were examined visually in this work (see below) which is an a posteriori
justification for the use of consensus scoring. Moreover, the LIECE model and the
electrostatic interaction energy are slightly worse than consensus scoring, while the
van der Waals efficiency is close to random picking probably because of the larger
molecular weight of the peptidic inhibitors than most of the compounds in the library.
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Inhibitor discovery by fragment-based docking and consensus
scoring
Upon sorting the compounds according to median rank and visual inspection of the
poses of the top 500 compounds, 19 of them were tested in a fluorogenic assay [18]
with the enzyme in solution. Six of these 19 compounds are active at concentra-
tions below 100 µM against PM I, PM II, and PM IV (compounds 1–6 in Table 3
and Figure 3). Therefore, the in silico screening approach is much more effective
than medium- and high-throughput screening procedures in vitro, for which hit rates
between 0.1% and 5% have been reported [19].
Three of the six actives have an IC50 ≤ 5µM for PM I and PM II. One should
note that these three compounds were identified in the database of the U.S. Na-
tional Cancer Institute, i.e, they do not originate from a malaria-related collection
of compounds. Five of the six inhibitors have a basic amino group which accord-
ing to the predicted binding modes can be either partially solvated or involved in
electrostatic interactions with the catalytic dyad. The binding mode of compound
1 is shown in Figure 4. Its positively charged tertiary amino group participates in
electrostatic interactions with the two carboxy groups of the Asp side chains in the
catalytic dyad. Furthermore, the hydroxyl group of compound 1 is involved in a hy-
drogen bond with the Ser79 side chain, located at the tip of the flap which covers the
central part of the substrate-binding site. Compound 6 has a primary amino group
which also forms a salt bridge with Asp 34 in the most favorable pose. On the other
hand, the partial solvation of the bulky tertiary amino group of compounds 2-4 and
lack of direct electrostatic interactions with the catalytic aspartates might be due to
the steric requirements of the former or the whole compound.
Remarkably, compound 3 is the antimalarial drug halofantrine [20], whose mech-
anism of action has not been fully elucidated although it was discovered more
than 40 years ago. It has been suggested that halofantrine reacts with hematin,
a metabolite of haemoglobin degradation which is toxic to plasmodia. Indeed, halo-
fantrine covalently binds to hematin in vitro [21]. Furthermore, quinine, an anti-
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malarial drug with some similarity to halofantrine, is capable of inhibiting the dimer-
ization of hematin to the non-toxic dimer β-hematin by plasmodia [22]. However,
stereoisomers of quinine did not significantly inhibit β-hematin formation but showed
antiplasmodial activity at µM concentrations [22], suggesting that a different mech-
anism of action is involved. Therefore, the docking results imply that halofantrine
acts as PM inhibitor in addition to its interference on hematin dimerization.
Substructure search and structure activity relationship
The three compounds with IC50 ≤ 5µM (i.e., 1, 3, and 4) share a common substruc-
ture (Figure 5), which was used to search in the Zinc library for further derivatives.
In total 40 molecules were retrieved and tested in the enzymatic assay, and seven
of them are active against PM II (compounds 7–13 in Table 3 and Figure 3). Com-
pounds 7–10 are similar to compounds 1, 3, and 4 but the affinity for PM II of
compound 10 is between 5 and 50 times poorer than the one of compounds 1, 3, 4
and 7–9. These values suggest that molecules with a three-ring system are more
potent than those with two rings. Furthermore, the longer the alkane chain the
higher the affinity, which can be explained by additional hydrophobic contacts with
the protein (Figure 4). On the other hand, halogen substituents on the ring system
(Cl and CF3, compounds 3 and 4) favor binding even if the alkane chain consists
of only four carbon atoms. Instead of three 6-membered rings, compounds 11 and
13 have a 5-membered ring fused to two 6-membered rings. Interestingly, a similar
substructure is shared between these compounds and an antimalarial drug with an
unknown mode of action, lumefantrine (benflumetol) [23]. Lumefantrine was docked
into PM II with SEED and FFLD, and its LIECE binding free energy is -8.2 kcal/mol.
Visual inspection of the 2D structure of the 13 inhibitors of PM II indicates that
they can be clustered into five different classes of compounds, three of which con-
tain a single member, namely compounds 5, 6, and 12 (Figure 3). Grouping of
the 13 inhibitors by 2D structural similarity using DAIM and a Tanimoto threshold of
0.950 and 0.975 yields 3 and 6 clusters, respectively. The similarity coefficients, as
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calculated using the DAIM fingerprints, are shown in Figure 6.
MD simulation study of halofantrine’s putative binding modes
Explicit water MD simulations were carried out to gain more information on the bind-
ing of halofantrine (compound 3) in the catalytic site of PM II. Two putative binding
modes were studied (Figure 7). In one binding mode (termed Amino In) the amino
group of halofantrine is located near Asp34, and its hydroxyl moiety is hydrogen-
bonded to Asp214. It was generated manually according to the binding of the amino
group and alkane chains in compound 1. The other binding mode (Amino Out) was
generated automatically by high-throughput docking as detailed in the Methods sec-
tion, and the amino group is partially exposed to the bulk and is not in contact with
the catalytic dyad. The protein appears to be stable in both MD runs, as indicated
by the low Cα RMSD and the small number of different structural clusters (Table 1).
The distance between the catalytic dyad oxygens (Asp34 Oδ–Asp214 Oδ) is larger in
the presence of halofantrine than in the complex with the EH58 inhibitor (PDB code
1LF3), and more so in the Amino In conformation (Figure 8), in which the amino
moiety of halofantrine is hydrogen bonded to Asp34. In the Amino Out conforma-
tion, it can be hydrogen bonded to the hydroxyl of Tyr192 or the carbonyl of Gly36,
but it is more often solvent-exposed (Table 4). In both binding modes, the hydroxyl
of Asp214 acts as donor in a hydrogen bond with the inhibitor’s hydroxyl group.
The mobility of halofantrine within the binding site can be assessed by calculat-
ing its RMSD after fitting of the protein atoms (Figure 9, top) and comparing with
the intrinsic flexibility of the inhibitor (Figure 9, bottom). The time series of RMSD
reveal a significant difference in the stability of the two putative binding modes.
In the Amino In conformation, the inhibitor’s RMSD reaches values of 0.7-0.8 nm
upon overlapping the protein backbone. The high RMSD values indicate that in the
Amino In binding mode halofantrine changes its orientation with respect to the tip of
the flap. Such displacement is not observed in the run started from the Amino Out
conformation. Finally, in one of the two Amino In simulations, the hydrogen bond
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between the amino group of the inhibitor and Asp34 is irreversibly lost after 43 ns,
leading to partial unbinding. Taken together, the MD simulations indicate that the
binding mode Amino Out (generated by automatic docking) is more stable than
Amino In (obtained by manual docking) although it is not possible to definitively
discard either.
Conclusions
To identify inhibitors of PM II, 4.6 million compounds were clustered according to
2D structural similarity resulting in about 40000 molecules which were then used
for fragment-based docking. Docking into the PM II active site was followed by
consensus scoring using four force field-based energy functions. A total of 19 com-
pounds were tested in an enzymatic assay, and three of them showed single-digit
µM inhibitory activity. One of these three inhibitors is halofantrine, an antimalarial
drug discovered more than 40 years ago whose mechanism of action has not been
elucidated yet. Four 50-ns explicit water MD simulations were performed to assess
the relative stability of two putative binding modes of halofantrine (with halofantrine’s
tertiary amino group involved in electrostatic interactions with the catalytic dyad or
pointing towards the solvent), but the analysis of the MD trajectories does not pro-
vide definitive evidence for either of the binding modes. A substructure search per-
formed using as query the common scaffold of the three inhibitors yielded another
seven active compounds. In conclusion, the fragment-based docking approach has
yielded a dozen of medium to low µM inhibitors belonging to five different classes
of compounds upon experimental testing of only 59 molecules. This success rate
is much higher than the 0.1-5% hit rates reported in medium- to high-throughput
screening campaigns in vitro. The in silico identification of halofantrine and a close
analogue of lumefantrine as PM II inhibitors provides further evidence that PMs are
interesting targets for the development of small-molecule anti-malarial drugs.
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Experimental Section
Computational methods
The in silico screening was carried out by a fragment-based procedure for high-
throughput docking [24–26]. The poses were scored by the median value of the
ranks of four energy functions. Three of these functions consisted of intermolecular
energy contributions, and the fourth was the binding free energy evaluated by the
LIECE approach [15].
Preparation of the PM II structure
The structure of PM II in the complex with the hydroxymethylamine inhibitor EH58
(PDB code 1LF3, [27]) was downloaded from the protein data bank [28]. This struc-
ture was chosen because of its slightly larger substrate-binding site, in particular
at the S′1 subpocket which has to accommodate the large P
′
1 group of EH58. In
fact, EH58 cannot be docked into structures with a smaller S′1 subpocket, e.g., the
complex of PM II with the protease inhibitor pepstatin (PDB code 1LS5 [27]). The
catalytic dyad was modeled with Asp214 protonated and Asp34 negatively charged,
according to a previous MD study [29]. All Arg and Lys side chains were positively
charged, while Glu and Asp side chains (except Asp214) were negatively charged.
The inhibitor and all water molecules were removed. Hydrogen positions were opti-
mized by energy minimization with the computer program CHARMM [30, 31], using
100 steps of steepest descent and 10000 steps of conjugate gradient minimization.
The distance dependent dielectric function ǫ(r) = r was used in the calculation
of the electrostatic energy where r is the interatomic distance in A˚. Non-bonding
interactions were truncated with a switching function at 14 A˚.
Preparation of the library of compounds
First, redundant entries were removed from the version 5 of the Zinc library [32],
which contains about 4.6 million molecules. Then the compounds were clustered
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according to their 2D structural features by the leader algorithm [33] as implemented
in DAIM [24] and using a Tanimoto coefficient of 0.995 as similarity threshold (note
that a high threshold value was used to weed out only the compounds that were very
similar to each other as the docking approach employed in this study is very effi-
cient). The compound with the highest similarity to all other molecules in the same
cluster was used for docking into the binding site. Each representative compound
was automatically decomposed into molecular fragments by DAIM, which was also
used to select the three fragments for docking by FFLD [26, 34]. This clustering
yielded about 40000 representative molecules upon removal of small molecules
that could not be decomposed in at least three fragments by DAIM. All input frag-
ments were minimized with CHARMM prior to docking, by 2000 steps of steepest
descents and 10000 steps of conjugate gradients. The distance dependent dielec-
tric function ǫ(r) = 4r was used in the calculation of electrostatic interactions during
minimization.
High-throughput fragment-based docking
High-throughput fragment-based docking was carried out using the methods de-
scribed in [11]. Briefly, fragments were docked to the binding site using the com-
puter program SEED [25, 35] which takes into account electrostatic solvation effects
by a generalized Born approach based on numerical evaluation of Born radii [36].
For each of the 40000 compounds, the most favorable poses of three of its frag-
ments were used as ”anchors” by the program FFLD [26, 34] for automatic docking
into the binding site. The binding modes were clustered by using the leader algo-
rithm with a similarity cutoff of 0.6 [25, 37]. A maximal number of 30 different poses
per molecule was allowed. The total number of docked compounds and poses was
approximately 40000 and 750000, respectively. Each pose was minimized within
the rigid protein using CHARMM by 500 steps of steepest descent and 10000 steps
of conjugate gradient using the dielectric function ǫ(r) = 4r.
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Consensus scoring
The following force field based energy functions were used for consensus scoring:
(1) The binding free energy evaluated by a three-parameter LIECE model (see next
section),
(2) the CHARMm [16] protein-compound electrostatic interaction energy with ǫ(r) =
4r and cutoff at 14 A˚,
(3) the CHARMm protein-compound van der Waals interaction energy (cutoff at
14 A˚) divided by the molecular weight of the compound (van der Waals efficiency),
(4) the TAFF [17] protein-compound interaction energy.
Electrostatic solvation energies (for LIECE) were calculated by numerical solution
of the finite-difference Poisson equation using the PBEQ module [38] in CHARMM
with an initial grid size of 1.0 A˚ and focusing to a final grid size of 0.4 A˚. CHARMm
and TAFF interaction energies were calculated after ligand minimization, using the
corresponding force field, in the rigid structure of PM II. Note that the TAFF force
field differs significantly from CHARMm as it was developed to reproduce molecular
structures by use of bonded and van der Waals interactions only, i.e., neglecting
electrostatic interactions.
Consensus scoring is generally preferable to the use of a single scoring func-
tion [39]. It has been reported that the median rank is more suitable than the aver-
age rank in consensus-scoring because the former is less sensitive to outliers [40].
Here, a median rank for each pose was calculated after ranking all poses indepen-
dently by each of the four energy functions. As an example, consider a certain pose
which is ranked 14th, 24th, 26th, and 27000th by the four functions: Its median rank
is 25 (while its average rank of 6766 is clearly affected by the very poor ranking of
only one of the four functions). The 750000 poses were sorted according to their
median rank and the top-scoring poses were examined visually. Since the protein
structure was kept rigid during docking it is very difficult to devise rules for the auto-
matic evaluation of the significance of the poses. It was not possible, for example,
to use the number of hydrogen-bonds between the compound and the protein as a
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filter since protein relaxation might promote formation of additional intermolecular
hydrogen bonds. Moreover, it is not simple to treat water molecules at the protein
surface, some of which can be involved in intermolecular hydrogen bonds [18]. Vi-
sual examination was used to discard high scoring compounds which nevertheless
did not seem to be properly docked. For example, a few compounds were discarded
because they did not form hydrogen bonds with the catalytic dyad, or because they
had a charged group located in a mainly hydrophobic subpocket.
LIECE model for PM II
LIECE uses only single-point energy evaluation on minimized structures [15] and is
therefore an efficient approximation of the original linear interaction energy method [41]
which requires computationally more expensive MD simulations [42]. Here, the free
energy of binding is approximated by a three-parameter LIECE model
∆Gbind = α∆EvdW + β(∆ECoul +∆Gsolv) + ∆Gtr,rot (1)
where ∆EvdW is the protein-ligand van der Waals interaction energy, ∆ECoul is the
Coulombic interaction energy calculated in vacuo, and ∆Gsolv is the electrostatic
contribution to the free energy of solvation. The parameters α and β are dimension-
less, while ∆Gtr,rot accounts for the loss of translational and rotational degrees of
freedom upon binding and is assumed to be independent of the bound ligand. The
three parameters α, β, and ∆Gtr,rot are determined by calculating ∆EvdW ,∆ECoul,
and ∆Gsolv for a series of compounds of known binding affinities and fitting accord-
ing to Equation (1). A set of 20 known peptidic inhibitors of PM II was used for
fitting, i.e., to derive the LIECE model for PM II. The 20 inhibitors are nine statines
(compounds 4–6 and 9–14 in Ref. [3]), nine hydroxyethylamines (compounds 20–27
and 29), and two hydroxypropylamines (compounds 30 and 31). The coordinates
of compounds 4, 11, 30, and 31 were taken from crystal structures of bound PM II
(PDB codes 1XE5, 1W6H, 1LEE, and 1LF2 [43], respectively). The coordinates of
these structures were superimposed on that of the protein with EH58 bound (PDB
code 1LF3), as used for docking. The coordinates of compound 4 were modified
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manually to account for the binding of compounds 5 and 6. Similarly, models of
the complexes of PM II with compounds 9–12, 13 and 14 were generated using
compound 11 as a template; the binding mode of the hydroxymethylamine inhibitor
EH58 (PDB code 1LF3, [27]) was used as a template for all other compounds where
crystal structures were not available. The coordinates of the inhibitors were refined
by 100 steps of steepest descents and 10000 steps of conjugate gradients en-
ergy minimization. A distance dependent dielectric function ǫ(r) = 4r was used in
the calculation of electrostatic interactions during minimization. Upon minimization,
∆ECoul was calculated with vacuum dielectric (ǫ = 1), without long-range truncation.
The electrostatic solvation ∆Gsolv was determined by solving the finite-difference
Poisson equation with ǫsolvent = 78.5 and ǫsolute = 1 using the PBEQ module [38] in
CHARMM with an initial grid size of 1.0 A˚ and focusing to a final grid size of 0.3 A˚.
MD simulations
Explicit-water MD simulations were carried out to discriminate between two halo-
fantrine binding modes obtained by automatic (mode Amino Out) and manual dock-
ing (mode Amino In). Two 50-ns runs differing in the initial random assignment of
atomic velocities were started from each binding mode (Table 1). The four MD simu-
lations were performed using version 3.3.3 of the GROMACS program [44, 45], with
the OPLS all atom force field [46] and TIP4P model of water [47]. Parameters for
halofantrine were derived as follows. First, its geometry was optimized by quantum-
mechanical ab initio approach with the 6-31Gd basis set, which is compatible with
the force field [46]. The partial charges were then determined by fitting them to the
electrostatic potential around the molecule using the Kollman-Singh method [48].
The calculation was performed with the computer program GAMESS [49]. The
topology for halofantrine was generated automatically by the topology builder mk-
top (Federal University of Rio de Janeiro, Brazil), which assigns OPLS atom types
(as used in GROMACS) according to the chemical moieties of the molecules, e.g.,
amide, ketone and alcohol.
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The protein/halofantrine complex was immersed in a truncated octahedral box
containing pre-equilibrated TIP4P waters [47]. Water molecules were removed from
the box if the distance between any solute atom and any atom of the water was less
than their sum of van der Waals radii. The edges of the box extended to at least
1.3 nm from the solute. Sodium and chloride ions were added randomly by replac-
ing water molecules in order to neutralize the charge of the system and maintain a
salt concentration of 0.1 M. Cation parameters derived by A˚qvist [50] were used for
Na+. Parameters for Cl− were taken from [51]. Before each MD simulation, inter-
nal strain was relaxed by energy minimization, until the maximal force on individual
atoms was smaller than 100 kJ mol−1 nm−1. After the minimization, a restrained
MD run was performed for 100 ps. During the restrained simulations, protein heavy
atoms were fixed to their initial positions with a force constant of 1000 kJ mol−1
nm−2. The restraints were released, and the system was equilibrated for 1 ns be-
fore data collection for analysis. During the MD runs, the LINCS algorithm [52] was
used to constrain the lengths of bonds, while water molecules were kept rigid by
use of the SETTLE algorithm [53]. The time step for the simulations was 2 fs. The
temperature and pressure were coupled to an external bath with Berendsen’s cou-
pling algorithm [54] (Pref = 1 bar, τP = 0.5 ps; Tref = 300 K; τT = 0.1 ps). Van der
Waals forces were truncated at 1.0 nm with a plain cutoff. Long-range electrostatic
forces were treated using the particle mesh Ewald method [55].
Structural analysis and clustering
Structural analysis was carried out by GROMACS utilities. Clustering was per-
formed as detailed in [56]. The figures with protein structures were generated
by VMD [57].
Hydrogen bond analysis
Hydrogen bonds between two residues were calculated with the program g hbond,
which is available in GROMACS. The criteria for a hydrogen bond were a donor
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(nitrogen or oxygen) to acceptor (oxygen) distance ≤ 0.35nm and an acceptor–
donor–hydrogen angle ≤30◦, which are the default parameters in GROMACS. In
addition, protein donor-acceptor pairs separated by a single water molecule were
also taken into account as hydrogen bonds.
Enzymatic assay
A previously described fluorogenic assay [18] was used for all compounds tested in
this work.
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Figure Legends
Figure 1: The LIECE model does not suffer of chance correlation. A total of 10000
random permutations of the ∆Gexp values were performed for the data presented in
Table 2. For each random permutation the correlation coefficient obtained by fitting
and the LOO cross-validated q2 were calculated (circles). The data shows that the
model with the best fit to the data is the true LIECE model (triangle). Note that there
exist a few random models with correlation coefficient higher than 0.9, but they have
a poor LOO cross-validated q2 because they fit the data by chance.
Figure 2: ROC plot of the individual energy terms and consensus scoring used in
this study. A total of 33 actives, 20 peptidic inhibitors and the 13 compounds iden-
tified in this study, were ranked together with the about 40000 docked compounds.
Consensus scoring (blue curve) is the preferred method if one examines up to about
the first 1000 compounds.
Figure 3: The 13 PM inhibitors discovered in this study. The structures of lume-
fantrine and doxorubicin are also shown as they share the same scaffold as com-
pounds 13 and 5, respectively.
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Figure 4: The binding mode of compound 1 obtained by docking. (Top) A diagram
of the binding mode, showing electrostatic interactions with Asp214 and Asp34, a
weak hydrogen bond with Ser79 of the flap and van der Waals interactions with 12
residues (shown in parentheses). (Bottom) The binding pocket and its location in
the protein (left), and the interactions of the inhibitor with the catalytic aspartates
and Ser79 (right).
Figure 5: The common scaffold of compounds 1, 3, and 4 (see Figure 3). The
substituent X stands for an alkane chain, n can be 1 or 2, R1 and R2 are aliphatic
or aromatic hydrocarbon rings. Groups A and B are adducts that replace R1, as in
compound 4.
Figure 6: Similarity between the active compounds. Similarity coefficients were
calculated with DAIM, based on the DAIM fingerprints [24]. For each compound the
average similarity coefficient, i.e., the similarity value averaged over the 12 other
compounds, is shown with a large circle and the circles are connected by a solid
line to guide the eye. Individual data points are shown by crosses.
Figure 7: The two putative binding modes of compound 3. (Left) Amino In: The
nitrogen of halofantrine’s tertiary amino group is located near the charged Asp34,
while its hydroxyl group is hydrogen-bonded to Asp214. The Tyr192 side chain does
not interact with halofantrine. The flap is shown by a red ribbon. The snapshot was
taken at 3.6 ns. (Right) Amino Out: The amino nitrogen of halofantrine is hydrogen-
bonded to Tyr192 and its hydroxyl to Asp214. The snapshot was taken at 30 ns.
Figure 8: Probability distribution of the minimal distance between the oxygens of the
catalytic dyads. The black line is the value of the distance in the crystal structure
1LF3 (d=0.295nm).
Figure 9: Time series of RMSD of halofantrine during explicit water MD simulations.
Heavy atoms RMSD are calculated after fitting the Cα atoms of PM II (top) or the
atoms of halofantrine (bottom). The four colored lines correspond to the two MD
runs started from each the Amino In (blue) and the Amino Out (red) binding modes.
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Tables
Starting Number of Cα RMSD [a] Nr. of protein Nr. of halofantrine
structure simulations [nm] clusters [b] clusters [b]
Amino Out 2 0.15 8 4
Amino In 2 0.15 8 2
Table 1: Summary of the explicit water MD simulations of the complex of PM II with
halofantrine. Each simulation was run for 50 ns. [a] Average value of the Cα root
mean square deviation between pairs of MD conformations. [b] Structural clustering
was performed with the Jarvis-Patrick algorithm [58] as described in [56].
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Inhibitor [a] ∆EvdW ∆ECoul ∆Gsolv ∆GLIECE ∆Gexp [b] Error
4 -65.5 11.0 -131.7 -13.0 -14.5 1.5
5 -58.2 13.3 -130.2 -11.3 -12.1 0.8
6 -69.5 -221.7 117.5 -13.0 -14.2 1.2
9 -60.4 -223.7 110.1 -11.6 -12.6 1.0
10 -63.5 -199.5 77.3 -12.6 -11.4 -1.3
11 -63.3 -214.1 100.8 -12.2 -11.8 -0.4
12 -53.0 -194.8 84.6 -9.9 -10.9 1.0
13 -69.8 -213.0 104.4 -13.3 -12.2 -1.0
14 -51.0 -213.7 79.9 -10.6 -10.0 -0.7
20 -53.3 -489.9 406.2 -8.7 -7.5 -1.3
21 -54.9 -484.9 397.7 -9.2 -7.5 -1.7
22 -51.9 -493.3 412.3 -8.3 -9.5 1.1
23 -52.5 -493.4 411.8 -8.5 -9.4 0.9
24 -59.1 -492.8 425.3 -9.2 -8.5 -0.6
25 -60.8 -497.8 425.9 -9.7 -10.3 0.6
26 -64.0 -500.3 427.5 -10.4 -9.8 -0.6
27 -58.3 -447.7 385.4 -8.7 -10.0 1.3
29 -57.5 -453.8 381.2 -9.1 -8.4 -0.6
30 -59.2 -202.0 98.1 -10.9 -10.6 -0.3
31 -60.9 -200.5 96.2 -11.3 -10.3 -1.0
Table 2: Calculated and experimental binding free energies of the 20 known PM II
inhibitors used for fitting of the three parameter LIECE model. The model is
∆GLIECE =0.20∆EvdW +0.05(∆ECoul+∆Gsolv)+6.0 kcal/mol. [a] Numbering of in-
hibitors is as in [3]. Note that the numbers of the known inhibitors are not in
boldface to distinguish them from those discovered in this study. [b] Experimen-
tal values of binding free energies are derived from KI values listed in [3], using
∆G = −RTln(KI). All energy values are in kcal/mol.
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IC50 [a]
PM I PM II PM IV ∆GLIECE [b]
Compound [µM] [µM] [µM] [kcal/mol]
Pepstatin 0.001 0.0002 0.002
Inhibitors identified by high throughput docking
1 4 5 21 -9.1
2 22 20 >100 -9.4
3 3 2 6 -9.0
4 2 2 5 -8.4
5 22 18 13 -9.9
6 37 56 52 -8.7
Inhibitors identified by substructure search
7 23 17 92 -8.1
8 3 5 9 -8.9
9 23 19 65 -7.7
10 24 95 100 -16.6
11 71 32 >100 -6.2
12 28 62 39 -7.6
13 41 24 80 -6.3
Table 3: Experimental validation of the in silico screening. [a] The half maximal
inhibitory concentration (IC50) was determined for the 13 compounds shown in Fig-
ure 3. The IC50 values represent the average of two repetitions of a fluorogenic
proteolysis assay [18]. The estimated error for this enzymatic assay is ±50%. The
values measured for pepstatin using the same assay in parallel are given as a refer-
ence. [b] The free energy of binding to PM II was calculated according to the LIECE
model (see Equation (1) and caption of Table 2). Note that ∆GLIECE systematically
overestimates the affinity of these inhibitors except for compounds 11 and 13.
Donor Acceptor Amino In Amino Out
HF-NH Asp34 92 0
HF-NH Gly36 or Tyr192 0 24
HF-OH Asp34 0 68
Asp214 HF-OH 94 91
Table 4: Hydrogen bonds between the protein and halofantrine (HF). The percent-
age of simulation frames in which a certain hydrogen bond (including hydrogen
bonds mediated by a single water molecule) is present is given for the simulations
Amino In and Amino Out.
Friedman and Caflisch 27
Suggestion for table of contents
High-throughput docking was used for the discovery of plasmepsin inhibitors.
40000 compounds were docked, 59 were tested in vitro and 13 were found active.
Compound 1 (IC50 = 5 µM) binds the catalytic site by forming a salt bridge with the









Displacement from active site
Intrinsic flexibility of halofantrine
